TG Therapeutics announced positive pharmacokinetic and pharmacodynamic results from a Phase 1 trial of subcutaneous BRIUMVI, demonstrating greater than 60% bioavailability and supporting quarterly dosing. Phase 3 data is expected by end of 2026 or early 2027, with potential approval in 2028 for what could be the first self-administered quarterly anti-CD20 therapy for multiple sclerosis.